CAR Stock Recent News

NEW YORK , June 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Avis Budget Group, Inc. ("Avis Budget" or the "Company") (NASDAQ: CAR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avis Budget investors who were adversely affected by alleged securities fraud between February 13, 2024 and February 10, 2025.

Canadian residential real estate offers overlooked opportunities for US investors amid shifting immigration trends. CAPREIT is a well-established REIT with stable occupancy, rising rents, and a solid 3.5% dividend yield backed by a 60% payout ratio and over 5% AFFO yield. Technical analysis shows no short-term price catalyst, but long-term dividend yield trends signal potential upside unless major negative events occur.

LOS ANGELES , June 24, 2025 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of the final deadline for a class action lawsuit against Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ: CAR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 16, 2024 and February 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before June 24, 2025.

LOS ANGELES , June 23, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ: CAR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 16, 2024 and February 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before June 24, 2025.

Investors can contact the law firm at no cost to learn more about recovering their losses

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avis To Contact Him Directly To Discuss Their Options

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Avis Budget Group, Inc. (“Avis Budget” or the “Company”) (NASDAQ: CAR) and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 25-cv-03332, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Avis Budget securities between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

NEW YORK , June 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR). Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose SAN JOSE, Calif. , June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.